Across TCGA pan-cancer cohorts, OR1J2 RNA is linked to patient survival in 17 of 34 cancer types, making it the most broadly survival-associated OR1J2 data layer compared with 3 for mutation status.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher OR1J2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR1J2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and COAD show a favorable association.
CESC, LIHC, and PAAD are the cancer types where OR1J2 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.